Ariad Pharmaceuticals (ARIA) News Today → Don’t expose yourself to stocks during the week (From DTI) (Ad) Free ARIA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative March 27, 2024 | finance.yahoo.comIDRx Appoints David P. Kerstein, M.D., as Chief Medical OfficerMarch 12, 2024 | finance.yahoo.comIDRx Strengthens Executive Team with Appointments of Tim Clackson, Ph.D., as CEO and Brad Dahms as CFO and CBOMarch 8, 2024 | msn.comWhat Is Donanemab? Eli Lilly’s Alzheimer’s Drug Gets Delayed Decision From FDAMarch 4, 2024 | bizjournals.comTakeda extends lease in Kendall Square through 2040February 13, 2024 | finance.yahoo.comIncyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D PrioritiesJanuary 3, 2024 | msn.comVeteran biotech entrepreneur Harvey Berger to lead startup Kojin TherapeuticsJanuary 3, 2024 | bizjournals.comHarvey Berger leaves biotech 'sidelines' for new CEO gigOctober 26, 2023 | msn.comBiogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's TreatmentOctober 12, 2023 | benzinga.comLeukemia Therapeutics Treatment Market Set to Achieve US$ 30,318.5 Million by 2033 at 7.1% CAGR | Future Market Insights Inc.September 6, 2023 | fortune.comKickstarter’s new finance chief is ultra-extroverted—and she credits that trait to her success as a ‘people-centric CFO’August 24, 2023 | finance.yahoo.comChronic Lymphocytic Leukemia Treatment Global Market Report 2023August 20, 2023 | thestreet.comAriad Stock Falls On Unusually High Volume (ARIA)July 19, 2023 | msn.comSecond Alzheimer’s drug to slow disease’s progression may be approved in the US this yearJuly 17, 2023 | cbsnews.comSecond Alzheimer's drug to slow disease's progression may be approved in the US this yearJune 28, 2023 | finance.yahoo.comSarissa Capital Urges Alkermes Shareholders to Vote "FOR" Sarah Schlesinger and "WITHHOLD" Incumbent Director Richard GaynorJune 26, 2023 | washingtonpost.comActivist Pro Tip: Don’t Put Your Girlfriend on the BoardMay 17, 2023 | marketwatch.comPonatinib Market Research | 2023-2030May 16, 2023 | marketwatch.comComprehensive Analysis of Cancer Treatment Drugs Market Trends and Growth 2023-2030May 14, 2023 | marketwatch.comIclusig Market Research | 2023-2030May 10, 2023 | marketwatch.comUterine Cancer Therapies and Diagnostic Market Forecast 2023-2030May 5, 2023 | marketwatch.comThe Global Targeted Drugs for NSCLC Market Size is expanding rapidly, with a CAGR of 12.2% from 2023 to 2030May 5, 2023 | marketwatch.comChronic Myeloid Leukemia (CML) Treatment Market 2023 [New Report forecast 2030] Current and Future TrendsMay 3, 2023 | msn.comEli Lilly Surges After Alzheimer's Treatment Succeeds; Biogen Also RisesMay 3, 2023 | marketwatch.comAcute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Analysis and Forecast to 2031May 3, 2023 | marketwatch.comCancer Drugs Market Applications and Types with Regional Analysis 2023-2031April 28, 2023 | marketwatch.comStomach Cancer Drugs Market (2023-2030) Rivalry Heats Up with New CAGR StatusApril 20, 2023 | benzinga.comGlobal Gastric Cancer Drugs Market Report 2023: Increasing Number of Obesity Cases and the Smoking Population Drives GrowthApril 20, 2023 | marketwatch.com2023-2030 Chronic Myeloid Leukemia (CML) Treatment Market Size with ManufacturesApril 19, 2023 | marketwatch.com2023-2030 Ponatinib Market Size Detailed Report with Downstream Market Analysis | Research by Absolute ReportsApril 12, 2023 | marketwatch.comUnlock Vital Data on Ponatinib market: Financial Summary, Shareholding Patterns, and Revenue Mix with Predicted CAGR of 5.1% from 2023-2030April 9, 2023 | marketwatch.comChronic Myeloid Leukemia (CML) Treatment Market 2023 Size and Forecast to 2031April 8, 2023 | marketwatch.comIn-depth Cancer Treatment Drugs report provides key estimates for predicting a projected CAGR of 5.2%April 7, 2023 | marketwatch.comPonatinib Market Research Analysis 2023-2030March 29, 2023 | marketwatch.comBile Duct Cancer Drug Market Growing Demand and Trends 2023 to 2031March 27, 2023 | marketwatch.comAnti-Cancer Drug Market Size and Forecast till 2031March 26, 2023 | marketwatch.comGlobal Cancer Drugs Market 2023 Projection, Growth Rate and Emerging Trends Analysis to 2030 By VMReportsMarch 22, 2023 | marketwatch.comIclusig Market Top Players and Forecast till 2031March 14, 2023 | marketwatch.comPonatinib Market Size 2023 to 2028 By Deployment, Growth Factor and Production costMarch 11, 2023 | marketwatch.comThe Evolution of Bile Duct Cancer Drug Market 2023: Future Developments and Trends by 2028March 10, 2023 | marketwatch.com2023-2029 Anti-Cancer Drug Market Size and Latest Trends Analysis | Research Report by Absolute ReportsMarch 8, 2023 | marketwatch.comGrowth Analysis on Proto-Oncogene Drgu Market Size 2023-2028 with Prominent Manufacturers | Research Report by Absolute ReportsMarch 7, 2023 | marketwatch.comForecasting the Future of Chronic Myeloid Leukemia (CML) Treatment Market: Analysing Emerging Trends and Opportunities 2023-2028March 4, 2023 | marketwatch.comGlobal Targeted Drug EGFR RTK Inhibitors for NSCLC Market Opportunities, Business Statistics Research Report 2030 By VMReportsMarch 4, 2023 | marketwatch.comGlobal Targeted Drugs for NSCLC Market Size Analysis, Share, Application, Opportunities Forecast to 2030 By VMReportsMarch 4, 2023 | marketwatch.comGlobal Anti-Cancer Drug Market 2023 Industry Share, Analysis of Competitive Landscape and Forecast 2030 By VMReportsMarch 1, 2023 | marketwatch.comGlobal Acute Lymphocytic / Lymphoblastic Leukemia Drugs Market Upcoming Trends, Opportunities by Types and Application to 2030 By VMReportsMarch 1, 2023 | marketwatch.comIn Depth Research on Uterine Cancer Therapies and Diagnostic Market Report 2023-2029February 27, 2023 | marketwatch.comGlobal Proto-Oncogene Drgu Market Size 2023 Business Strategies, Growth Analysis, Regional Demand, 2030 Forecast Research Report By VMReportsFebruary 27, 2023 | marketwatch.comBile Duct Cancer Drug Market 2023 Size, Share, Growth, Analysis, Trends and Forecast to 2028February 22, 2023 | marketwatch.comChronic Myeloid Leukemia (CML) Treatment Market is Booming by Size, Revenue, Trend and Top Growing Companies 2023-2028 Get Ariad Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARIA and its competitors with MarketBeat's FREE daily newsletter. Email Address This consistently signaled gains of 453%... 610%... and even 1036%... (Ad)It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade. Register for the imminent briefing here. ARIA Media Mentions By Week ARIA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARIA News Sentiment▼0.000.68▲Average News Sentiment ARIA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARIA Articles This Week▼00▲ARIA Articles Average Week Get Ariad Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARIA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARIA) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsBill Clinton Backing Biden Replacement???The Freeport SocietyUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ariad Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.